





an Open Access Journal by MDPI

Annexin Proteins Family in Cancer

Guest Editors:

Prof. Dr. Antonello Petrella

Department of Pharmacy, University of Salerno, via Giovanni Paolo II 132, 84084 Fisciano (SA), Italy

Dr. Raffaella Belvedere

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, SA, Italy

Deadline for manuscript submissions:

closed (10 December 2022)

Message from the Guest Editors

This Special Issue highlights the role of the protein family of annexins in the progression of various types of tumors. They are involved in numerous cell functions, as cell death/proliferation, differentiation, motility, particularly through their interaction with cytoskeletal components, oxidative stress, secretion of microvesicles. In cancer, the annexins have been discovered as relevant proteins in different phases of tumor progression, as oncogenic or oncosuppressor agents in a tissue-specific manner and depending on the protein concerned.

We are pleased to invite you to contribute with original research articles as well as review ones that will stimulate continuing efforts to understand the role of annexins in the tumor progression and provide valuable insights that may translate to diagnostic and/or therapeutic opportunities.

We publish high-quality articles including basic, translational, and clinical studies on all tumor types.

Research areas may include (but are not limited to) the following:

- *in vitro* cell cultures
- in vivo tumor models
- 2D/3D cell systems
- clinical studies.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us